[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1106562T1 - Κυκλικα πεπτιδια τα οποια εχουν δραση αγωνιστη υποδοχεα μελανοκορτινης-4 - Google Patents

Κυκλικα πεπτιδια τα οποια εχουν δραση αγωνιστη υποδοχεα μελανοκορτινης-4

Info

Publication number
CY1106562T1
CY1106562T1 CY20071100594T CY071100594T CY1106562T1 CY 1106562 T1 CY1106562 T1 CY 1106562T1 CY 20071100594 T CY20071100594 T CY 20071100594T CY 071100594 T CY071100594 T CY 071100594T CY 1106562 T1 CY1106562 T1 CY 1106562T1
Authority
CY
Cyprus
Prior art keywords
melanocortin
cyclic peptides
agent activity
receptor agent
receptor
Prior art date
Application number
CY20071100594T
Other languages
English (en)
Inventor
Li Chen
Adrian Wai-Hing Cheung
Xin-Jie Chu
Waleed Danho
Joseph Swistok
Yao Wang
Keith Alan Yagaloff
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1106562T1 publication Critical patent/CY1106562T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε πεπτίδια τα οποία κυκλοποιούνται μέσω δισουλφιδικών δεσμών ή δεσμών λακτάμης τα οποία έχουν δράση αγωνιστή υποδοχέα μελανοκορτίνης-4 (MCR-4) χρήσιμα για την θεραπευτική αντιμετώπιση της παχυσαρκίας.
CY20071100594T 2000-08-30 2007-05-07 Κυκλικα πεπτιδια τα οποια εχουν δραση αγωνιστη υποδοχεα μελανοκορτινης-4 CY1106562T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918400P 2000-08-30 2000-08-30
PCT/EP2001/009630 WO2002018437A2 (en) 2000-08-30 2001-08-21 Cyclic peptides having melanocortin-4 receptor agonist activity

Publications (1)

Publication Number Publication Date
CY1106562T1 true CY1106562T1 (el) 2012-01-25

Family

ID=22860145

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100594T CY1106562T1 (el) 2000-08-30 2007-05-07 Κυκλικα πεπτιδια τα οποια εχουν δραση αγωνιστη υποδοχεα μελανοκορτινης-4

Country Status (35)

Country Link
US (1) US7045591B2 (el)
EP (1) EP1315750B1 (el)
JP (1) JP4217069B2 (el)
KR (1) KR100483300B1 (el)
CN (1) CN100491396C (el)
AR (2) AR030504A1 (el)
AT (1) ATE353918T1 (el)
AU (2) AU2001284026B2 (el)
BR (1) BR0113637A (el)
CA (1) CA2420058C (el)
CY (1) CY1106562T1 (el)
CZ (1) CZ2003584A3 (el)
DE (1) DE60126624T2 (el)
DK (1) DK1315750T3 (el)
EC (1) ECSP034503A (el)
ES (1) ES2280393T3 (el)
HR (1) HRP20030126B1 (el)
HU (1) HUP0303078A3 (el)
IL (2) IL154575A0 (el)
JO (1) JO2454B1 (el)
MA (1) MA27681A1 (el)
MX (1) MXPA03001721A (el)
MY (1) MY137457A (el)
NO (1) NO20030916L (el)
NZ (1) NZ523989A (el)
PA (1) PA8527201A1 (el)
PE (1) PE20020483A1 (el)
PL (1) PL366630A1 (el)
PT (1) PT1315750E (el)
RU (1) RU2239642C1 (el)
SI (1) SI1315750T1 (el)
TW (1) TWI248941B (el)
WO (1) WO2002018437A2 (el)
YU (1) YU15603A (el)
ZA (1) ZA200301015B (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453027A1 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
CA2523408A1 (en) * 2003-05-09 2004-11-18 Novo Nordisk A\S Peptides for use in treating obesity
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
CA2527881A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
AU2004275928B2 (en) * 2003-09-30 2010-03-11 Novo Nordisk A/S Melanocortin receptor agonists
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
EP1751273B1 (en) * 2004-04-08 2011-02-16 Astellas Pharma Inc. Compound ws727713
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
JP2008519007A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
US20080280820A1 (en) * 2004-11-04 2008-11-13 Ulrich Sensfuss Novel Peptides for Use in the Treatment of Obesity
WO2006048449A2 (en) * 2004-11-04 2006-05-11 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
EP1809667A1 (en) * 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
JP2008542358A (ja) * 2005-05-31 2008-11-27 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨格環化メラノコルチン刺激ホルモン（αＭＳＨ）類似物
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US20070025902A1 (en) * 2005-07-15 2007-02-01 3M Innovative Properties Company Recovery of fluorinated carboxylic acid from adsorbent particles
US20080015304A1 (en) 2006-07-13 2008-01-17 Klaus Hintzer Aqueous emulsion polymerization process for producing fluoropolymers
GB2430437A (en) * 2005-09-27 2007-03-28 3M Innovative Properties Co Method of making a fluoropolymer
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CA2673229A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Methods for the synthesis of cyclic peptides
KR101500018B1 (ko) * 2007-02-16 2015-03-06 쓰리엠 이노베이티브 프로퍼티즈 캄파니 물로부터 불소화합물계 물질을 제거하는 시스템 및 방법
US20080264864A1 (en) 2007-04-27 2008-10-30 3M Innovative Properties Company PROCESS FOR REMOVING FLUORINATED EMULSIFIER FROM FLUOROPOLMER DISPERSIONS USING AN ANION-EXCHANGE RESIN AND A pH-DEPENDENT SURFACTANT AND FLUOROPOLYMER DISPERSIONS CONTAINING A pH-DEPENDENT SURFACTANT
RU2450017C2 (ru) * 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
JP5312324B2 (ja) * 2007-07-19 2013-10-09 株式会社トクヤマ ヒダントイン環を有する化合物及びその製造方法
HUE026184T2 (en) * 2008-03-27 2016-05-30 Gruenenthal Gmbh (Hetero-) aryl-cyclohexane derivatives
NZ600210A (en) 2008-03-27 2013-08-30 Gruenenthal Chemie Substituted 4-aminocyclohexane derivatives
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
CN102712674A (zh) 2009-11-23 2012-10-03 帕拉丁科技公司 黑皮质素-1受体-特异性的线性肽
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
AU2015323769A1 (en) * 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
WO2017066754A1 (en) 2015-10-15 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for the treatment of depression and anxiety
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CN106496005B (zh) * 2016-10-20 2019-04-09 上海毕得医药科技有限公司 一种4-(4-氯苯基)环己酮的合成方法
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
US10745444B2 (en) * 2017-04-17 2020-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN118530294A (zh) * 2024-05-10 2024-08-23 浙江大学 一种芳基二胺固载连接子、其前体以及制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5858972A (en) 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
AU763510B2 (en) 1999-03-29 2003-07-24 Procter & Gamble Company, The Melanocortin receptor ligands

Also Published As

Publication number Publication date
AR030504A1 (es) 2003-08-20
CA2420058C (en) 2009-04-07
IL154575A0 (en) 2003-09-17
AU8402601A (en) 2002-03-13
ATE353918T1 (de) 2007-03-15
JP2004507558A (ja) 2004-03-11
HRP20030126B1 (en) 2009-01-31
DE60126624T2 (de) 2007-11-22
CA2420058A1 (en) 2002-03-07
EP1315750B1 (en) 2007-02-14
DE60126624D1 (de) 2007-03-29
IL154575A (en) 2008-12-29
SI1315750T1 (sl) 2007-06-30
JO2454B1 (en) 2008-10-09
DK1315750T3 (da) 2007-06-11
WO2002018437A2 (en) 2002-03-07
BR0113637A (pt) 2004-02-25
KR100483300B1 (ko) 2005-04-15
ECSP034503A (es) 2003-04-25
TWI248941B (en) 2006-02-11
HUP0303078A2 (hu) 2003-12-29
RU2239642C1 (ru) 2004-11-10
CZ2003584A3 (cs) 2003-08-13
US7045591B2 (en) 2006-05-16
PT1315750E (pt) 2007-05-31
NO20030916D0 (no) 2003-02-27
YU15603A (sh) 2006-05-25
WO2002018437A3 (en) 2002-06-06
MXPA03001721A (es) 2003-05-27
CN100491396C (zh) 2009-05-27
PL366630A1 (en) 2005-02-07
US20020143141A1 (en) 2002-10-03
NZ523989A (en) 2004-08-27
ZA200301015B (en) 2004-05-05
HUP0303078A3 (en) 2012-02-28
KR20030061788A (ko) 2003-07-22
NO20030916L (no) 2003-02-27
CN1451017A (zh) 2003-10-22
MA27681A1 (fr) 2006-01-02
PE20020483A1 (es) 2002-06-06
AU2001284026B2 (en) 2007-03-01
HRP20030126A2 (en) 2005-10-31
AR061422A2 (es) 2008-08-27
PA8527201A1 (es) 2002-04-25
EP1315750A2 (en) 2003-06-04
ES2280393T3 (es) 2007-09-16
MY137457A (en) 2009-01-30
JP4217069B2 (ja) 2009-01-28

Similar Documents

Publication Publication Date Title
CY1106562T1 (el) Κυκλικα πεπτιδια τα οποια εχουν δραση αγωνιστη υποδοχεα μελανοκορτινης-4
DK1017713T3 (da) Cykliske antagonister af C5a-receptorer og G-protein-koblede receptorer
CY1110362T1 (el) Ν-(2-αρυλαιθυλο)βενζυλαμινες ως ανταγωνιστες του 5-ητ6 υποδοχεα
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
DE60218852D1 (de) Verbindungen
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1109487T1 (el) Ανταγωνιστες τυπου ουριας του υποδοχεα p2y1 χρησιμοι στην αγωγη θρομβωτικων καταστασεων
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
ATE398630T1 (de) Zyklische conotoxin-peptide
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
ATE356623T1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
WO2003104266A3 (en) PEPTIDES AND PEPTIDOMIMETICS FOR INHIBITING THE ACTIVITY OF THE PROSTAGLANDIN F2 DOLLAR G (A) RECEPTOR
DE69917278D1 (de) Heterocyclyl sulphonamid derivate
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
NO20055309L (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
CY1113476T1 (el) ΠΕΠΤΙΔΙΑ ΚΑΙ ΠΕΠΤΙΔΟΜΙΜΗΤΙΚΑ ΧΡΗΣΙΜΑ ΓΙΑ ΑΝΑΣΤΟΛΗ ΤΗΣ ΔΡΑΣΤΙΚΟΤΗΤΑΣ ΥΠΟΔΟΧΕΑ ΠΡΟΣΤΑΓΛΑΝΔΙΝΗΣ F2a
CY1117548T1 (el) Ν-(2-αρυλαιθυλο)βενζυλαμινες ως ανταγωνιστες του 5-ηt6 υποδοχεα
ATE468352T1 (de) Cyclische peptide, die als urotensin-ii- antagonisten wirken
SE0303418D0 (sv) New use 1
TR199902914T2 (xx) �zole sistolik hipertansiyonu tedavi y�ntemi.
CY1105815T1 (el) Οφθαλμικη συνθεση που πepιλαμβανει ασκομυκινη
UY26913A1 (es) Péptidos cíclicos selectivos